Period of onset and lack of clinical manifestation of hepatotoxicity after commencing highly active antiretroviral therapy by Ugiagbe, RA & Ugiagbe, EE
63Nigerian Journal of Clinical Practice • Jan-Mar 2012 • Vol 15 • Issue 1
Original Article
Abstract
Aim: The period of onset of hepatotoxicity varies between cohorts as do their clinical manifestations. Clinical 
manifestations of hepatotoxicity that have been previously reported include fatal portal hypertension, dress syndrome, 
and lipodystrophy syndrome. The aim of this study was to determine the period of onset and clinical manifestation of 
hepatotoxicity after commencing HAART.
Materials and Methods: This study was carried out on patients with HIV on HAART attending infectious disease 
clinic, gastroenterology clinic or admitted into the medical wards of University of Benin Teaching Hospital. Patients with 
HIV but not on HAART were used as controls. A clinical evaluation and relevant laboratory investigations were done. 
Hepatotoxicity was defined using a standardized toxicity grade scale.
Results: A total of 84 cases and 42 controls were studied. The mean ages were 35.2 ± 9.9 years and 35.5 ± 9.0 years 
for the cases and the controls respectively. Over 70% of the study population and controls were females. The overall 
incidence of hepatotoxicity was 17.85% and severe hepatotoxicity occurred in 10.71% of the patients. Over 80% of 
liver enzyme elevations occurred within 3 months, most of which were asymptomatic.
Conclusion: This study shows that over 80% of enzyme elevations occurred within 3 months and were mostly 
asymptomatic. There is a need for regular monitoring of liver function tests at short intervals in HIV patients starting 
HAART since most of the cases of hepatotoxicity found in this study occurred early and were asymptomatic.
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Introduction
The advent of antiretroviral therapy (ART) has resulted 
in a significant decrease in morbidity and mortality 
among HIV‑infected patients.[1,2] However, ART is often 
complicated by drug‑related toxicities.[3,4] Hepatotoxicity is 
one of the most relevant adverse effects of ART owing to 
its frequency and the fact that it can lead to interruption 
of therapy, hepatitis, and death.[5] Incidence rates of 
hepatotoxicity vary greatly with different locations and 
study designs. According to the different definitions used 
in each study the overall frequency of grade 3 or 4 liver 
toxicity induced by HAART in HIV patients ranges from 
1% to 18%.[6,7] The period of onset of hepatotoxicity varies 
between cohorts[8,9] as do their clinical manifestations.[10,11] 
Clinical manifestations of hepatotoxicity that have been 
previously reported include fatal portal hypertension,[12] 
dress syndrome[11] (drug rash, eosinophilia and systemic 
symptoms), and lipodystrophy syndrome consisting of 
central obesity, buffalo hump, wasting of extremities, 
hyperlipidemia, and insulin resistance.[10] The aim of 
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this study was to determine the period of onset as well as 
clinical manifestations of HAART‑induced hepatotoxicity 
in HIV‑infected patients.
Materials and Methods
The study was carried out in the Department of Medicine, 
University of Benin Teaching Hospital (UBTH), Benin City, 
Edo State, Nigeria. It was carried out on patients with HIV 
about to be started on HAART, attending infectious disease 
clinic, gastroenterology clinic, or admitted into the medical 
wards. Patients with HIV but who were not yet qualified 
to be started on HAART, following the Nigerian National 
guidelines for initiating HAART,[13] served as controls. 
Consenting patients were recruited consecutively and 
each patient was followed up for 24 weeks. The duration 
of the study was from July 2008 to July 2009. The study 
design was a prospective cohort study. Patients were eligible 
if they were diagnosed with HIV and had normal liver 
function tests, commencing HAART. Exclusion criteria 
included patients with HIV and pulmonary tuberculosis, 
pregnant women, patients already on HAART, recent 
hepatitis B or C infection, and patients with abnormal liver 
function tests. Informed and written consent was sought 
from each patient before enrolment into the study. The 
approval of the Hospital Ethics Committee was obtained 
before commencement of the study. A questionnaire was 
administered.
Each patient had a detailed history taken from him including 
alcohol use and drug history, and a physical examination was 
conducted. The patient’s height without shoes was measured 
with the patient standing erect and looking straight ahead 
(coronal plane) using the stadiometer and the result was 
recorded in meters to the nearest 0.01 m.
The body weight (without shoes on and wearing light 
clothing only) was measured using a weighing scale and 
recorded in kilograms to the nearest 0.01 kg.
The body mass index (BMI) was then calculated using the 
formula
BMI=Weight (kg)/Height (m)2.
The following investigations were carried out on each 
patient
•  Packed  cell  volume  (PCV)  and WBC count  (total, 
differential, and absolute lymphocyte count) were done 
using the Symex automated machine.
•  Liver function tests (AST, ALT, total bilirubin, conjugated 
and unconjugated bilirubin, alkaline phosphatase, and 
Gamma Glutamyl Transpeptidase‑ GGT). ALT and 
AST were assayed using spectrophotometry. The normal 
reference values used in UBTH are ALT≤ 12 U/L and 
AST≤12 U/L following the recommendations of the 
manufacturer of the kits. Like ALT/AST assays, other 
LFTs were done using spectrophotometry.
•  Hepatitis  B  surface  antigen  (HBsAg)  and  antibody 
to hepatitis C virus were determined using the global 
diagnostic rapid tests and ELISA kits.
•  CD4  cell  count was  done  using Cyflow  automated 
machine.
The patients were then commenced on any of the HAART 
regimens below based on the protocol used in PEPFAR clinic 
in UBTH, which corresponds with the Nigerian National 
guidelines for initiating HAART.[13]
Stavudine (d4T)+Lamivudine (3TC)+Nevirapine (NVP) 
or Efavirenz (EFV)
Zidovudine (ZVD\AZT)+Lamivudine (3TC)+Nevirapine 
(NVP) or Efavirenz (EFV)
Tenofovir (TDF) or Abacavir (ABC)+Emtricitabine (FTC) 
or Lamivudine (3TC)+Nevirapine (NVP) or Efavirenz 
(EFV)
Didanosine (ddI)+Lamivudine (3TC) or Emtricitabine 
(FTC)+Nevirapine (NVP) or Efavirenz (EFV).
After 4 weeks of therapy, 5 ml of venous blood was 
collected from each patient and this was used for analysis 
of serum alanine aminotransferase (ALT), serum aspartate 
aminotransferase (AST), serum bilirubin, and alkaline 
phosphatase. This was again repeated at the 12th and 
24th week of therapy. The controls were followed up 
3 monthly, during the period of the study, with CD4 counts 
for evidence of deterioration and possible commencement of 
HAART. Five milliliters of venous blood was also collected 
from the controls at baseline, 4, 12, and 24 weeks just as for 
the cases. Those patients that had elevated liver enzymes 
had a repeat screening for HBsAg and anti‑HCV if they 
were negative at the initial screening.
Those who tested positive for HBsAg or anti‑HCV on 
recruitment had a repeat screening at 24 weeks to establish 
persistence of infection. This was done for both the cases 
and controls.
Definition of Hepatotoxicity
A standardized toxicity grade scale, modified from that 
used by the AIDS clinical trial group which is now widely 
used,[3,10,14] was employed in this study. Patients’ serum ALT 
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Grade 1=value within 1.25 – 2.5×ULN
Grade 2=value within 2.6 – 5×ULN
Grade 3=value within 5.1 – 10×ULN
Grade 4=value>10×ULN.
Changes in serum total bilirubin (TBR) were classified based 
on changes relative to ULN:
Grade 0=value<1.1×ULN
Grade 1=value within 1.1 – 1.5×ULN
Grade 2=value within 1.6 – 2.9×ULN
Grade 3=value within 3 – 5×ULN
Grade 4=value>5×ULN.
For the purpose of analysis, grades 1 and 2 were grouped 
as mild‑to‑moderate hepatotoxicity and grades 3 and 4 as 
severe hepatotoxicity.[15]
Elevations in levels of alkaline phosphatase were interpreted 
as evidence of cholestasis.
Clinical Manifestations
The clinical features assessed include abdominal pain, 
nausea/vomiting, jaundice, and rash. This was recorded at 
baseline, 4, 12, and 24 weeks.
Statistical analysis
The data obtained were analyzed using the statistical 
package for social sciences (SPSS) version 15.0. The 
Chi‑square test was used to compare the various ARV 
regimens and hepatotoxicity. It was also used to compare 
risk factors for hepatotoxicity such as hepatitis B or C 
coinfection, alcohol use, and underweight. The student 
t‑test was used for continuous variables. Two‑way analysis of 
variance (ANOVA) was used to compare means of variables 
involving more than two groups. The level of significance 
was set at P value<0.05 and confidence level at 95%.
Results
A total of 84 patients and 42 controls were used for the study. 
Each patient and control were followed up for 24 weeks and 
the results were analyzed. Baseline characteristics were 
recorded as median and interquartile range for continuous 
variables and percentages for categorical variables. The 
baseline characteristics of the cases and controls are 
summarized in Table 1. The controls had a significantly 
greater amount of alcohol consumption than the cases; 
however, both groups were similar regarding other factors 
such as BMI, HBsAg, anti‑HCV, CD4 cell count, ALT, AST, 
ALP, TBR, PCV, sex, and age.
All 84 cases were commenced on HAART. The most 
commonly used regimens were Lamivudine, Zidovudine, 
Nevirapine (LZN) accounting for 50 (59.5%) of cases. This was 
followed by Lamivudine, Stavudine, Nevirapine (LSN) which 
were used in 14 (16.7%) of the cases. Tenofovir, Emtricitabine, 
Nevirapine (TEN), and Lamivudine, Zidovudine, Efavirenz 
(LZE) each were prescribed for 6 (7.1%) of cases. Tenofovir, 
Emtricitabine, Efavirenz (TEE), Lamivudine, Stavudine, 
Efavirenz (LSE), and Lamivudine, Emtricitabine, Effavirenz 
(LEE) each were used in 5 (6.0%), 2 (2.4%), and 1 (1.2%) of 
cases respectively as shown in Table 2.
Table 1: Baseline characteristics of the study 
population
Control n=42 Cases n=84 P value
Sex
Male 8 (19%) 23 (27.4%) 0.306
Fmale 34 (81%) 61 (72.6%)
Age (years) 34 (30–41) 32 (28–40) 0.439
PCV (%) 35 (33–37) 32 (28–35) 0.124
ALT (U/l) 8.5 (8–10) 8 (7–10) 0.133
AST(U/l) 11 (10–12) 11.5 (10–12) 0.324
ALP (U/l) 14 (10–28) 18 (14–25) 0.088
GGT (U/l) 14 (10–28) 20 (18–22) 0.085
TBR (mg/dl) 0.8 (0.2–1.0) 0.7 (0.4–1.0) 0.648
Conj BR (mg/dl) 0.4 (0.08–0.5) 0.4 (0.2–0.5) 0.324
Total protein (g/dl) 
6 (5.8–6.6)
6 (5.6–6.5) 0.183
Albumin (g/dl) 3.6 (3.5–4.0) 3.5 (3.2–3.8) 0.125
CD4 counts/ml 510 (431.8–656.3) 168 (88.8–250.5) 0.248
Total WBC.
(×109 counts/l)
5.2 (4.4–6.1) 3.8 (2.9–4.7) 0.124
Lymphocytes 
(×109 counts/mm3)
2.1 (1.8–2.8) 1 (0.9–1.6) 0.052
Neutrophils 
(×109 counts/mm3)
2.2 (1.6–2.9) 1.9 (1.6–2.6) 0.613
HbsAg 1 (2.4%) 2 (2.4%) 0.707
Anti‑HCV 1 (2.4%) 1 (1.2%) 0.557
Alcohol (g/day) 31 (28–36) 9 (3–18) 0.030
BMI (kg/m2) 24.5 (21.2–28.5) 22.5 (20.1–26.3) 0.462
Continuous variables are expressed as median (interquartile), and 
categoric variables are expressed as absolute numbers (%). PCV = Packed 
cell volume, ALT = Alanine aminotransferase, AST = Aspartate 
aminotransferase, ALP = Alkaline phosphatase, GGT = Gamma glutamyl 
transpeptidase, TBR = Total bilirubin, Conj BR = Conjugated bilirubin, 
WBC = White blood cell count, HBsAg = Hepatitis B surface antigen, Anti 
HCV = hepatitis C virus antibodies

















LZN = Lamivudine+Zidovudine+Nevirapine, LZE = Lamivudine+Zidovud
ine+Efaviranz, TEE = Tenofovir+Emtricitabine+Efaviranz, LSE = Lamivu
dine+Starvudine+Efavirenz, LSN = Lamivudine+Stavudine+Nevirapine, 
TEN = Tenofovir+Emtricitabine+Nevirapine, LEE = Lamivudine+Emtricita
bine+Effavirenz
66 Nigerian Journal of Clinical Practice •Jan-Mar 2012 • Vol 15 • Issue 1
Ugiagbe and Ugiagbe: Hepatotoxicity of HAART
Of the 84 cases analyzed, 10.71% (9 cases) had severe 
hepatotoxicity while 7.14% (6 cases) had mild‑to‑moderate 
hepatotoxicity. In contrast, of the 42 controls, none (0) 
had severe hepatotoxicity while 9.52% (4 cases) had 
mild‑to‑moderate hepatotoxicity as shown in Table 3. There 
was a statistically significant difference in severe hepatotoxicity 
between cases and controls (χ2=4.846, df=1, P=0.028).
Five of the 15 cases of hepatotoxicity in the cases (33.3%) 
occurred by 4 weeks of therapy, 53.3% (8 of 15 cases) 
occurred by 12 weeks while the remaining 13.3% (2 of 
15 cases) occurred by 24 weeks. This is depicted in Table 4. 
Thus 86.6% of cases of hepatotoxicity occurred within 
12 weeks of therapy.
Of the 84 cases, 5 (6.0%) developed clinical symptoms after 
commencement of HAART; rashes occurred in 3 (3.6%) and 
2 (2.4%) had nausea and vomiting. Hepatotoxicity (mild to 
moderate) was identified in one patient who developed rash 
at 4 weeks accounting for 6.7% (1 of 15 cases) of patients 
with hepatotoxicity. This is shown in Table 5. There was 
however no significant association between hepatotoxicity 
and clinical symptoms (χ2=1.803, df=2, P=0.406).
Discussion
In this study, the overall incidence of hepatotoxicity of 
HAART was 17.85%. This includes severe (grade 3 and 4 
ALT/AST elevation) and mild to moderate (grades 1 and 2 
changes) hepatotoxicities. Severe hepatotoxicity occurred 
in 10.71% of the patients while mild to moderate accounted 
for 7.14%. The overall finding contrasts with a study 
conducted in Madrid, Spain, where the overall incidence 
of hepatotoxicity was 31% but severe hepatotoxicity is 
similar to their finding of 9%.[16] A similar study was carried 
out in New York where hepatotoxicity was analyzed as 
mild to moderate (grades 1 and 2) and severe (grades 3 
and 4) and a low incidence of 1.1% was reported for severe 
hepatotoxicity.[15] The analysis of hepatotoxicity as severe 
and mild‑to‑moderate hepatotoxicity is often ignored by 
most investigators because mild‑to‑moderate hepatotoxicity 
resolves whether antiretroviral therapy is continued or 
not and are of limited clinical relevance.[3] The incidence 
of severe hepatotoxicity after HAART as reported by 
most clinical trials ranges between 1% and 18%.[6,7,16] 
The finding of 10.7% in this study falls within that range. 
Among controls, 4.8% (4 of 42) had mild‑to‑moderate 
hepatotoxicity, none had severe hepatotoxity. This contrasts 
sharply with the finding of severe hepatotoxicity of 10.7% 
and mild‑to‑moderate hepatotoxicity of 7.1% in cases. One 
explanation for the occurrence of hepatotoxicity in controls 
would be the consumption of alcohol (median 31 g/day) in 
these patients. Others include a flare up of viral hepatitis, 
HIV itself and probably the small sample size of the controls. 
There was a statistically significant difference between the 
frequency of severe hepatotoxicity in the cases compared 
with the controls (χ2=4.846, df=1, P=0.028).
In this study 33.3% (5 of 15) of cases of hepatotoxicity 
occurred at 4 weeks of therapy, 53.3% (8 of 15) at 12 weeks 
while 13.3% (2 of 15) occurred at 24 weeks. This shows that 
86.6% of cases occurred within 12 weeks of therapy. This 
finding compares favorably with the study done in South 
Africa where 80% of their patients developed hepatotoxicity 
within the first 12 weeks.[9] In contrast, the study conducted 
in Spain reported 60% of cases of hepatotoxicity occurring 
after the first 12 weeks and suggested that liver enzyme 
elevations occurred as a consequence of a toxic cumulative 
effect. The finding in this study strengthens previous 
definition of drug‑induced hepatotoxicity as an acute event 
occurring within the preceding 3 months of commencement 
of the drug.[17,18] This has made some investigators to separate 
the first 12 weeks of therapy from the complete treatment 
episode.[3] The occurrence of five cases of hepatotoxicity at 
4 weeks and eight cases at 12 weeks would suggest different 
mechanisms, the former due to hypersensitivity reaction and 
the latter due to mitochondrial toxicity.[15] Two cases still 
occurred at 24 weeks suggesting that in HIV patients on 
HAART, hepatotoxicity still occurs after 12 weeks though 
with a decreasing frequency.
Table 3: Incidence of hepatotoxicity in cases and 
control
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Total 84 84 84 84 84
ALT = Alanine aminotransferase, AST = Aspartate aminotransferase, 
TBR = Total bilirubin. Between hepatotoxicity and chronic hepatitis 
B in the cases, χ2=17.073, df=2, Fisher’s P=0.0146, and in controls, 
χ2=9.732, df=1, P=0.010
Table 5: Clinical manifestation of hepatotoxicity















Total 15 69 84
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This study shows that over 94% of patients with hepatotoxicity 
were asymptomatic. This is similar to previous reports where 
the majority of HIV patients on HAART had asymptomatic 
enzyme elevations.[4,19] However, this study did not show 
manifestation of hepatotoxicity in the form of clinical 
features such as abdominal pain, nausea and vomiting, 
rash or jaundice. This contrasts sharply with a report from 
South Africa where rash and nausea were independently 
associated with hepatotoxicity.[9] On the other hand, most 
other studies did not relate clinical manifestations with 
hepatotoxicity.[8,14,16]
In summary, over 80% of liver enzyme elevations occurred 
within 3 months and were mostly asymptomatic. There 
is a need for regular monitoring of liver function tests 
(ALT/AST), at short intervals, in HIV patients starting 
HAART because of the risk of early hepatotoxicity and 
asymptomatic presentations.
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